Few Receive the Shingles Vaccine Because of Cost to Doctors
Posted May 26 2010 3:47pm
It’s a classic good-news, bad-news story.
The vaccine against shingles, already shown to be effective, is both safe and well-tolerated, researchers found after following more than 38,000 participants in the randomized trial that led to the 2006 approval of the vaccine.
On the other hand, few people are getting the vaccine, and for a variety of reasons — including its cost — researchers noted in a separate study. Both analyses appear in the May 4 issue of the Annals of Internal Medicine.
The findings highlight the lack of a comprehensive approach to adult vaccination in the U.S., according to James Donahue, DVM, PhD, and Edward Belongia, MD, both of the Marshfield Clinic Research Foundation in Marshfield, Wis.